Drug Profile


Alternative Names: Bupivacaine/meloxicam extended release; HTX-002/HTX-009; HTX-009/HTX-002; HTX-011; HTX-011-19; HTX-011A; HTX-011B; Meloxicam/bupivacaine; Meloxicam/bupivacaine extended release

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Heron Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pipecolic acids; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 10 Aug 2017 Updated efficacy data from phase II trials in Postoperative pain released by Heron Therapeutics
  • 09 Aug 2017 Heron Therapeutics plans a second phase III trial for Postoperative-pain (Prevention)
  • 09 Aug 2017 Heron Therapeutics plans a third phase III safety and pharmacokinetics study in Postoperative-pain (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top